
    
      Patient is randomized to receive either 0.025% topical capsaicin or vehicle control (placebo)
      for 8 weeks. After one week wash-out period, patients will be switched to the other group for
      8 weeks.

      Outcome will be assessed by visual analog scale, neuropathic pain scale, SF-MPQ, SF-36.
      Safety and tolerability will be recorded.
    
  